Newsmeme!
Discover News you didn't know existed
Dyspnea
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
Published August 29, 2008, 9:40 am, Centre Daily Times
ImClone Systems Incorporated (NASDAQ: IMCL) today announced overall survival results from BMS CA225-099 (BMS-099), an open-label Phase 3 study of ERBITUX(R) (cetuximab) in combination with a taxane and carboplatin in the first-line treatment of all histological subtypes of advanced non-small cell lung cancer (NSCLC).
New England Journal Of Medicine Publishes Phase III Results Of VELCADE(R) (Bortezomib) For Injection In Previously ...
Published August 29, 2008, 6:12 am, Medical News Today
Millennium: The Takeda Oncology Company announced the publication of results from the 682 patient, randomized, Phase III VISTA(1) trial in this week's edition of the New England Journal of Medicine.
Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery
Published August 27, 2008, 3:12 pm, News-Medical-Net
Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously ...
Published August 27, 2008, 2:00 pm, PR Newswire via Yahoo! Finance
Millennium: The Takeda Oncology Company today announced the publication of results from the 682 patient, randomized, Phase III VISTA trial in this week's edition of the New England Journal of Medicine.
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After ...
Published August 27, 2008, 4:00 am, PR Newswire via Yahoo! Finance
Novartis announced today that Gleevec® tablets* has been granted priority review status by the US Food and Drug Administration as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors .
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |